NCT07542314Not yet recruitingPhase 4
Phase 4 Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Patients With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting (ENHANCE)
Sarepta Therapeutics, Inc.1 site in 1 country20 target enrollmentStarted: August 31, 2026Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Status
- Not yet recruiting
- Sponsor
- Sarepta Therapeutics, Inc.
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Cohort 1: Number of Participants with ALI
Study Overview
Brief Summary
The primary objective of this study is to evaluate acute liver injury (ALI) rates associated with ELEVIDYS with the addition of sirolimus as an adjunct prophylactic immunosuppression agent.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 4 Years to — (Child, Adult, Older Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Cohort 1 only: Is male at birth, ambulatory, and ≥ 4 years of age at the time of dosing.
- •Cohort 1 only: Is eligible for commercial ELEVIDYS.
- •Cohort 2 only: Is male at birth and has previously received ELEVIDYS in a commercial setting after pre-treatment with sirolimus and corticosteroids.
- •Cohort 1 only: Participants who are sexually active must agree to use, for the entire duration of the study, a condom and the female sexual partner must also use a medically acceptable form of birth control (eg, oral contraceptive).
- •Has (a) parent(s) or legal guardian(s) who is (are) able to understand and comply with the study visit schedule and all other protocol requirements, or is ≥ 18 years of age and personally able to understand and comply with the protocol requirements.
- •Either has a parent or legal guardian who is willing to provide informed consent, or is ≥ 18 years of age and able to provide informed consent independently.
Exclusion Criteria
- •Cohort 1 only: Contraindicated to receive ELEVIDYS per the United States Package Insert (USPI).
- •Cohort 1 only: Has serological evidence of current, chronic, or active human immunodeficiency virus, hepatitis C, or hepatitis B infection.
- •Has a medical condition or confounding circumstances (eg, prior traumatic limitation for mobility or significant behavioral comorbidity) that, in the opinion of the Investigator, might compromise:
- •The participant's ability to comply with the protocol-required procedures, and/or
- •The participant's well-being or safety, and/or
- •The clinical interpretability of the data collected from the participant
- •Cohort 1 only: Has a symptomatic infection (eg, upper respiratory tract infection, pneumonia, pyelonephritis, meningitis) within 4 weeks prior to Day
- •Cohort 1 only: Has received a live virus vaccine within 4 weeks or inactive vaccine within 2 weeks of the Day 1 visit or expects to receive a vaccination during the first 3 months after Day
- •Cohort 1 only: Any confounding factors that would prevent the use of oral sirolimus including a known hypersensitivity to sirolimus or any of its excipients.
- •Cohort 1 only: Any wounds or recent injuries that, in the opinion of the Investigator, would be at risk of dehiscence or impaired healing in the setting of sirolimus administration.
- •Other inclusion/exclusion criteria may apply, per protocol.
Arms & Interventions
Cohort 1: ELEVIDYS
Other
Participants will receive ELEVIDYS in a commercial setting on Day 1. Participants will also receive sirolimus, glucocorticoids and antibiotics orally.
Intervention: ELEVIDYS (Drug)
Cohort 1: ELEVIDYS
Other
Participants will receive ELEVIDYS in a commercial setting on Day 1. Participants will also receive sirolimus, glucocorticoids and antibiotics orally.
Intervention: Sirolimus (Drug)
Cohort 1: ELEVIDYS
Other
Participants will receive ELEVIDYS in a commercial setting on Day 1. Participants will also receive sirolimus, glucocorticoids and antibiotics orally.
Intervention: Antibiotics (Drug)
Cohort 2: ELEVIDYS
No Intervention
Participants who have previously received ELEVIDYS in a commercial setting after prophylactic treatment with sirolimus and corticosteroids will participate in one study visit during which a muscle biopsy will be performed. No study treatment will be administered in this cohort.
Cohort 1: ELEVIDYS
Other
Participants will receive ELEVIDYS in a commercial setting on Day 1. Participants will also receive sirolimus, glucocorticoids and antibiotics orally.
Intervention: Glucocorticoids (Drug)
Outcomes
Primary Outcomes
Cohort 1: Number of Participants with ALI
Time Frame: 12 weeks
Secondary Outcomes
- Cohort 1: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs)(Day 1 up to Week 24)
- Cohort 1: Number of Participants with Infections, Edema, Wound-healing Complications, Hyperlipidemia, Angioedema, and Interstitial Lung Disease/Non-infectious Pneumonitis(Day 1 up to Week 24)
- Cohort 1: Number of Participants with Hepatic Adverse Events, Hepatic Biomarkers, and Laboratory Assessments Indicative of Either Acute Hepatocellular Injury or Acute Liver Dysfunction(Day 1 up to Week 24)
- Cohort 1: Number of Participants with Severe ALI(Day 1 up to Week 24)
- Cohort 1: Number of Participants with ALI(Day 1 up to Week 24)
- Cohort 1: Duration of ALI(Day 1 up to Week 24)
- Cohort 1: Amount of Steroid Use(Day 1 up to Week 24)
- Cohort 1: Duration of Steroid Use(Day 1 up to Week 24)
- Cohort 1: Quantity of ELEVIDYS Dystrophin Protein Expression as Measured by Western Blot(Week 12)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 2
A study to evaluate KER-050 as a monotherapy or in combination with Ruxolitinib in Myelofibrosis.Myelofibrosis2023-507468-38-00Keros Therapeutics Inc.56
Recruiting
Phase 1
The Study of Safety and Preliminary Efficacy of ALT001 in Patients With MultIple System Atrophy-Cerebellar TypeMultiple System Atrophy - Cerebellar Subtype (MSA-C)NCT07514923yilong Wang20
Recruiting
Phase 2
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal CancerColorectal CancerNCT07474727Multitude Therapeutics Inc.180
Recruiting
Phase 1
Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid TumorsNCT07487168H. Lee Moffitt Cancer Center and Research Institute24
Recruiting
Phase 4
Study to allow access to dabrafenib and/or trametinib for subjects that are benefiting from dabrafenib and/or trametinib treatment in a Novartis or GSK sponsored study.2023-509318-13-00Novartis Pharma AG17